Department of Medicine, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Cambridge, UK.
COPD. 2011 Apr;8(2):79-95. doi: 10.3109/15412555.2011.558542.
Chronic obstructive pulmonary disease (COPD) is a multicomponent condition that is characterized by partially reversible airflow obstruction. Serum surfactant protein D (SP-D) is synthesized by type II pneumocytes and Clara cells and participates in surfactant homeostasis and pulmonary host defense. Serum levels of SP-D are raised in individuals with COPD but there is no correlation between the serum level of SP-D and the severity of airflow obstruction. Serum SP-D is present in different forms that may have more utility as a biomarker for COPD. We report here the development of new monoclonal antibodies to full length and cleaved SP-D. We have assessed these and existing antibodies in 98 individuals with COPD recruited to the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) cohort. Our data show that neither monoclonal antibodies to full length nor cleaved SP-D provide additional information over that obtained with a polyclonal antibody. Moreover, levels of serum nitrosylated-SP-D did not correlate with serum level of SP-D or any clinical phenotype of COPD. The measurement of modified SP-D is of limited value in characterising individuals with COPD.
慢性阻塞性肺疾病（COPD）是一种多组分疾病，其特征为部分可逆的气流阻塞。血清表面活性剂蛋白 D（SP-D）由 II 型肺泡细胞和克拉拉细胞合成，参与表面活性剂的动态平衡和肺宿主防御。COPD 患者的血清 SP-D 水平升高，但血清 SP-D 水平与气流阻塞的严重程度之间无相关性。血清 SP-D 以不同形式存在，可能作为 COPD 的生物标志物更具实用性。我们在此报告了针对全长和裂解 SP-D 开发的新单克隆抗体。我们在 98 名 COPD 患者中评估了这些单克隆抗体和现有的抗体，这些患者被招募到评估 COPD 纵向以确定预测替代终点（ECLIPSE）队列中。我们的数据表明，全长或裂解 SP-D 的单克隆抗体均不能提供比多克隆抗体更多的信息。此外，血清亚硝基化-SP-D 水平与血清 SP-D 水平或 COPD 的任何临床表型均无相关性。改良 SP-D 的测量在确定 COPD 患者方面价值有限。
